Merck KGaA to Acquire Bio-Techne (TECH) for $11.3B at 36% Premium; Shares Surge 19%

Merck KGaA announced on June 25, 2026 that it will acquire Bio-Techne (TECH) in an all-cash deal at $73 per share, implying a total enterprise value of approximately $11.3 billion (~€9.9 billion). According to Bloomberg and the joint press release, the offer represents a ~36% premium to Bio-Techne's one-month VWAP and a ~24% premium to its June 24 closing price. TECH surged more than 22% premarket before settling to a ~19% gain during regular trading.

Deal Terms: $73 Cash, 36% Premium

Under the definitive merger agreement announced jointly on June 25, 2026:^{[Bio-Techne IR]}

• Price: $73 per share, all cash
• Total enterprise value: ~$11.3 billion (~€9.9 billion)
• Premium: ~36% to the one-month VWAP; ~24% to the June 24 closing price
• Financing: Combination of Merck KGaA's existing cash and new debt
• Expected close: Late 2026 to early 2027, pending regulatory clearances and Bio-Techne shareholder approval

Bio-Techne's board approved the transaction unanimously, and Merck KGaA's relevant governance bodies have also signed off. MarketScreener cited the enterprise value as ~$11.5 billion, a slight variance from the $11.3 billion in the official press release; this article follows the official figure.

Two Mercks: Merck KGaA vs. Merck & Co.

The acquirer here is Merck KGaA, headquartered in Darmstadt, Germany — a diversified group spanning pharmaceuticals, life science tools, and semiconductor materials, traded in Frankfurt under the ticker MRK and founded in 1668. It is entirely independent of Merck & Co. (NYSE: MRK), the U.S. pharmaceutical giant. The two companies share a name but have no ownership or control relationship.

Merck KGaA operates its life science business in the U.S. under the MilliporeSigma brand, supplying laboratory reagents, consumables, and instruments to researchers. The Bio-Techne acquisition is an extension of that platform.

Bio-Techne: Upstream Life Science Tools

Founded in 1976 and headquartered in Minneapolis, Minnesota, Bio-Techne (TECH) supplies high-purity proteins — cytokines, growth factors — antibodies, immunoassays, and protein analysis instruments to biotech, pharma, and academic customers. Its products are embedded in drug discovery, preclinical research, and biomanufacturing workflows.

The company operates two segments:

• Protein Sciences: The largest revenue contributor, with FY2025 full-year segment net sales of $870.2 million, up ~5% YoY. Products include cytokine/growth factor proteins, ELISA kits, and protein electrophoresis and quality control tools.^{[Bio-Techne Q4 FY2025 IR]}
• Diagnostics and Spatial Biology: Blood chemistry quality controls, immunoassays, and IVD products, alongside a growing presence in spatial biology — profiling gene and protein expression while preserving tissue architecture.

Recent financials:

• FY2025 (ended June 2025) net sales: ~$1.2 billion, up ~5% YoY
• FY2026 Q3 net sales: $311.4 million, down ~2% YoY; organic revenue also down ~2%
• FY2026 Q3 bright spots: mid-single-digit growth in proteomics instruments, high-teens growth in spatial biology, and GMP protein growth of nearly 50% (excluding fast-track customers)

Strategic Rationale: Building a Full-Workflow Life Science Platform

Per the official press release, Merck KGaA sees strong product-line complementarity between its MilliporeSigma life science division and Bio-Techne:^{[PR Newswire]}

• The combined company would span the full life science workflow — from basic research and translational science through drug development, testing, and commercial manufacturing
• Key focus areas: multi-omics, spatial biology, precision diagnostics, and cell and gene therapy
• Bio-Techne's protein analysis capabilities and GMP-grade proteins would strengthen Merck KGaA's Process Solutions business

On synergies, Merck KGaA targets ~€140 million in annual cost savings by year three post-close. The company also expects the deal to be immediately accretive to group EBITDA pre margins and to MilliporeSigma's sales growth upon close, with EPS pre turning accretive by year three.

Biggest Deal in a Decade: How It Compares to Sigma-Aldrich

At $11.3 billion, this is Merck KGaA's largest acquisition since the ~$17 billion Sigma-Aldrich deal closed in 2015.^{[BioInformant]}

Side-by-side comparison:

Sigma-Aldrich was the largest acquisition in Merck KGaA's then-347-year history, itself eclipsing the ~$13 billion Serono deal from 2007. The Bio-Techne transaction is smaller in absolute terms, but stands out as a major strategic move given the ongoing consolidation in the life science tools sector.

Stock Reaction and Market Context

TECH surged more than 22% premarket before trimming gains to ~19% in regular trading, with shares changing hands in the low-$70s range.^{[Investing.com]}

Notably, activist fund Ananym Capital Management had already disclosed a position in Bio-Techne ahead of June 25 and was publicly pushing the board to explore strategic alternatives, including a sale to a larger strategic buyer — exactly the outcome that materialized here.

More broadly, the life science tools sector has faced headwinds in the first half of 2026, with organic growth slowing across several public companies. Bio-Techne itself posted a ~2% organic revenue decline in FY2026 Q3. Against that backdrop, Merck KGaA's decision to pay a premium speaks to its conviction in the sector's long-term growth trajectory — though TECH's trajectory from here will hinge on how smoothly regulatory review and integration proceed.

Key Milestones Ahead

• Shareholder vote: Bio-Techne will call a special meeting for stockholders to vote on the merger
• Antitrust review: U.S. DOJ/FTC and EU competition authorities must sign off — Merck KGaA already holds significant share in global life science tools markets
• Expected close: Late 2026 to early 2027

This content is for informational purposes only and does not constitute investment advice, trading advice, or any guarantee of returns.